China’s fast-track investigator-initiated trial model drew scrutiny after reports of three deaths in expedited trials, spotlighting oversight and trust gaps in the system. The deaths have raised questions about how quickly trials are launched, monitored, and audited when timelines are compressed. For sponsors and investigators, the episode underscores the operational risk that can follow “speed-first” clinical pathways—particularly when site capabilities and inspection schedules lag the pace of enrollment. Companies relying on IITs for rapid data generation may need to re-check monitoring plans and escalation pathways for safety signals. Regulators and stakeholders will likely face pressure to clarify requirements for site auditing, data validation, and reporting thresholds during accelerated studies. The next updates will determine whether China’s expedited framework tightens risk-control controls or stays aligned to shorter review-and-start timelines.